The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season.
Moderna announced on Friday that its updated COVID-19 mRNA vaccine, Spikevax, has received authorization in Canada for those aged six months and older.
Add Asianet Newsable as a Preferred Source
The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season. The firm added that the pre-filled syringe doses of the vaccine for the market will be made domestically. While the drug substance will be produced at the company’s facility in Laval, Quebec, fill-finish operations will be completed by Novocol Pharma in Cambridge, Ontario.
Get updates to this developing story <directly on Stocktwits.<
